PUBLIC COMPANY
save$ESPREsperion Therapeutics, Inc.
$ESPRAnn Arbor, MI, USupdated 2mo ago
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
community read0 votes
pipeline
6
marketed
2
phase 3
0
catalysts ytd
2
approvals ytd
2
recalls ytd
0
Pipeline(6)
pipeline depth6 products
2Preclinical2Marketed2Unknown
Marketed
(bempedoic acid + ezetimibe)
Heterozygous Familial Hypercholesterolemia (heFH)
Marketedbempedoic acid
Heterozygous Familial Hypercholesterolemia (heFH)
ATP-citrate synthase
Preclinical(bempedoic acid + ezetimibe + rosuvastatin)
Cardiovascular Risk Factors
PreclinicalESP-2001
Primary Sclerosing Cholangitis
drugNEXLETOL
1 INDICATIONS AND USAGE NEXLETOL is indicated: to reduce…
ATP-citrate synthase
drugNEXLIZET
1 INDICATIONS AND USAGE NEXLIZET, a combination of bemped…
ATP-citrate synthase
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)
- phase4Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women
- —Bempedoic Acid Pregnancy Surveillance Program
- phase3Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo
Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (6)
- Mar 13, 26grantKoenig Sheldon L. · President and CEO723,760 sh
- Mar 13, 26grantKoenig Sheldon L. · President and CEO647,460 sh
- Mar 13, 26grantHalladay Benjamin · Chief Financial Officer247,430 sh
- Mar 13, 26grantHalladay Benjamin · Chief Financial Officer221,270 sh
- Mar 13, 26grantLooker Benjamin · Chief Legal Officer300,840 sh
- Mar 13, 26grantLooker Benjamin · Chief Legal Officer269,230 sh
🐶 Hiring Signal
News
- Summit’s ‘self-inflicted’ stumble; Esperion’s take-private dealSummit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast c…biopharma_dive · 3mo ago
Data sources
last refreshed 14m ago
Found something off?
comments(0)
5-min edit window · permanent after that